PCR Journal Club

This analysis shows that diabetic patients undergoing revascularization face substantially higher 5-year rates of all-cause mortality, myocardial infarction, repeat revascularizations, and stroke compared to non-diabetic patients.

This sub-analysis of EBC MAIN aimed to determine if intracoronary imaging use during LM bifurcation PCI was associated with fewer MACE, for patients treated with a planned dual‐stenting strategy versus provisional strategy.

This patient-level analysis of randomized trials comparing PCI vs CABG for the treatment of low-to-intermediate CAD involving the LM confirms the absence of long-term differences in mortality between revascularization techniques, regardless of the clinical presentation.

While the choice between PCI and CABG for LMCA disease continues to be one of the most controversial topics, patient characteristics & comorbidities must be taken into account, as must the external validity of the results of RCTs in the real world, as the SWEDEHEART registry does.

The investigator initiated, multicentre, randomised, EBC TWO trial compared a provisional strategy with a systematic culotte technique in patients with true non-LMS bifurcation disease. At one year, there was no difference between the groups in terms of the composite endpoint of all-cause mortality, MI or TVR....

Provisional stenting (PS) is the default approach for treating most coronary bifurcation lesions (CBL). The side branch (SB) can be compromised after main vessel (MV) stenting in up to 6-18 % of cases. The 17th Expert consensus document of the European Bifurcation Club details strategies for...

The OPTIMUM study evaluates the outcomes in patients with complex CAD, including significant LM disease, its equivalent, or MVD CAD, undergoing percutaneous revascularization in addition to guideline directed medical therapy (GDMT) versus GDMT alone.

The current analysis examines patient characteristics and outcomes following LM PCI performed in NSC in England and Wales.

The purpose of the ROLEX Registry (Revascularization Of LEft main with resolute onyX) was to explore outcomes using a more contemporary drug eluting stent platform which is more suitable for LM PCI.

The HOST-REDUCE-POLYTECH-ACS trial was a randomised, parallel-group multicentre trial with a 2x2 factorial design testing two independent hypotheses, one of which was the non-inferiority of durable polymer drug-eluting stents (DP-DES) to biodegradable polymer drug-eluting stents (BP-DES) in patients with ACS. In this post-hoc analysis, the authors...